Shanghai Securities News China SecuritiesGanli PharmaceuticalsOn September 24th, the company announced that it had signed a Technology Transfer and Supply Agreement with Fundao Oswaldo Cruz-Bio-Manguinhos (FZ), a public laboratory under the Brazilian Ministry of Health, and BIOMM SA (BIOMM), a Brazilian biopharmaceutical company. The company also signed a Supply Framework Agreement with BIOMM. According to the announcement, the contract value of the Supply Framework Agreement is expected to be no less than RMB 3 billion, with a term of 10 years.
This collaboration is centered around Brazil's Production Development Partnership Program (Parcerias para oDesenvolvimento Produtivo, or PDP). A key initiative of Brazil's national public health system, the program aims to promote local pharmaceutical production through technology transfer from multinational pharmaceutical companies, ensuring a long-term, stable supply of essential medicines in Brazil. As early as 2014, Gan & Lee Pharmaceuticals and BIOMM established a comprehensive and in-depth partnership, introducing their superior resources to the Brazilian market. On May 12th of this year, a delegation led by Brazilian Minister of Health Alexandre Padilha and BIOMM CEO Heraldo Marchezini visited Gan & Lee Pharmaceuticals ' headquarters for strategic discussions and signed a PDP project cooperation commitment letter. Gan & Lee Pharmaceuticals, the first Chinese pharmaceutical company to be included in the Brazilian PDP program, marks a new phase in China-Brazil biopharmaceutical cooperation. This contract signing formalizes the PDP project partnership commitment, laying the foundation for Gan & Lee Pharmaceuticals to maintain a stable supply of insulin to the Brazilian market over the next decade.
The announcement revealed that during the evaluation and screening process for the insulin glargine PDP project organized by the Brazilian government, the proposal jointly submitted by Gan & Lee Pharmaceuticals, BIOMM, and FZ was ultimately approved and confirmed as the sole approved proposal for the project. Under the Technology Transfer and Supply Agreement, Gan & Lee Pharmaceuticals will transfer insulin glargine-related technology to FZ and supply insulin glargine API and injection to BIOMM. Under authorization from Gan & Lee Pharmaceuticals, BIOMM will transfer its filling process to FZ and provide insulin injection and pen-type insulin syringes. As the technology contractor and final purchaser, FZ has committed to purchase the corresponding products from BIOMM at the agreed-upon purchase volume and price over the next 10 years. It is anticipated that the stable supply of insulin to Brazil's public healthcare system over the next decade will depend significantly on this collaboration. This collaboration will not only help alleviate the long-term medication access challenges faced by Brazilian diabetics but also enhance the self-sufficiency of the public healthcare system.
On the other hand, the Supply Framework Agreement signed between Gan & Lee Pharmaceuticals and BIOMM represents an independent commercial collaboration. The contract covers insulin glargine raw materials, injections, and insulin pens, with an estimated cumulative order value of no less than RMB 3 billion over ten years. Gan & Lee Pharmaceuticals stated that this contract signing is in line with the company's strategic development direction. If successfully implemented, it is expected to have a positive impact on the company's operating performance in 2025 and subsequent years, contributing to improving the company's overall profitability. (Ye Li)

https://finance.eastmoney.com/a/202509243522684743.html